Health · Pharma & Biotech · 1 hr ago
BioNTech cancer vaccine misses one goal in pivotal trial
BioNTech’s experimental mRNA vaccine for head and neck cancer failed to meet one of its main goals in a pivotal trial.
The vaccine is still experimental.
The trial had two primary goals, also called endpoints.
The vaccine missed the first goal.
The available information does not say whether it met the second goal.
It also does not say what happens next.
BioNTech’s experimental mRNA cancer vaccine missed one of two primary endpoints in a pivotal trial.
The vaccine is being studied for head and neck cancer.
The trial results add to the obstacles faced by the vaccine, Endpoints News reported.
The article does not identify which endpoint was missed or provide trial results.
- Who
- BioNTech.
- What
- Its experimental mRNA cancer vaccine missed one of two primary endpoints in a pivotal trial.
- When
- The results were reported on October 13, 2026.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- BioNTech
- Vaccine type
- Experimental mRNA cancer vaccine
- Cancer type
- Head and neck cancer
- Trial status
- Pivotal trial
- Primary endpoints
- Missed one of two
Sources
Related news
Beam shares early data on rare-disease gene-editing therapy
At least 90 lawsuits allege weight-loss drugs caused vision loss
Syndax ends Niktimvo development for lung disease after Phase 2 failure
Early research links GLP-1 drugs to signs of slower biological aging
Experts raise safety concerns about Neurocrine’s Prader-Willi drug
US FDA supports planned trial of StemSmart therapy for Crohn’s disease
UCLA specialists outline how doctors can choose between two MASH drugs
Bimatoprost eye lens shows early promise for cataracts and glaucoma
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Resmetirom Linked to Lower Heart Risks Than Semaglutide in Liver Disease Analysis
Merck’s eye drug meets main study goal, but results are mixed
